Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Deutsche Boerse AG  >  Roche Holding AG    RHO5   CH0012032048

ROCHE HOLDING AG

(RHO5)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Roche Pharmaceuticals Names New CEO as O'Day Leaves to Head Gilead -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2018 | 02:56am EST

(Adds detail about departing CEO, Gilead confirmation)

 
 By Cristina Roca 
 

Roche Holding on Monday said it has appointed a new chief executive for its Roche Pharmaceuticals business to replace the current CEO, who is leaving the company to head Gilead Sciences.

The Swiss pharmaceuticals company said Monday that CEO Daniel O'Day will step down as of Dec. 31, and that it is appointing William Anderson to the post effective Jan. 1.

Separately on Monday, Gilead said in a press release that it has appointed Mr. O'Day as chief executive and chairman of its board effective March 1. The U.S. biopharmaceutical company named Gregg Alton interim CEO for the period between Jan. 1 and Mr. O'Day's start date.

Roche said Mr. Anderson will also join its corporate executive committee.

Mr. Anderson is currently chief executive of Genentech, a Roche subsidiary company. He has worked for Roche since 2006.

Separately, Roche said it was proposing Hans Clevers for election to its board of directors. Mr. Clevers is a professor of molecular genetics at University Medical Center Utrecht, the company said.

Write to Cristina Roca at cristina.roca@dowjones.com; @_cristinaroca

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES -1.88% 63.96 Delayed Quote.4.03%
ROCHE HOLDING AG 1.16% 297 Delayed Quote.22.64%
ROCHE HOLDING AG 1.28% 299.85 Delayed Quote.21.63%
ROCHE HOLDING AG -0.14% 245.6 Delayed Quote.14.10%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING AG
10:55aDicerna Shares Rise on Collaboration With Novo Nordisk
DJ
06:12aROCHE : CHMP recommends EU approval of Roche's Kadcyla for the adjuvant treatmen..
AQ
06:12aCHUGAI PHARMACEUTICAL : Wins Prize in 7th WICI Japan Award for Excellence in Int..
AQ
06:12aROCHE : Promedior Enters Into Definitive Merger Agreement to Be Acquired By Roch..
AQ
01:01aGENENTECH : to Present New and Updated Data for Seven Approved and Investigation..
BU
01:00aRoche to present new and updated data for seven approved and investigational ..
GL
11/15Health Care Up As Trump Administration Plan Not As Onerous As Feared -- Healt..
DJ
11/15CHMP recommends EU approval of Roche's Kadcyla for the adjuvant treatment of ..
GL
11/15CHMP recommends conditional EU approval of Roche's Polivy for people with pre..
GL
11/11CHUGAI PHARMACEUTICAL : Files a New Drug Application for Satralizumab for NMOSD ..
AQ
More news
Financials (CHF)
Sales 2019 62 045 M
EBIT 2019 22 162 M
Net income 2019 14 729 M
Debt 2019 2 382 M
Yield 2019 3,09%
P/E ratio 2019 17,8x
P/E ratio 2020 17,0x
EV / Sales2019 4,12x
EV / Sales2020 3,93x
Capitalization 253 B
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 313,00  CHF
Last Close Price 296,05  CHF
Spread / Highest target 20,2%
Spread / Average Target 5,73%
Spread / Lowest Target -24,0%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG14.10%255 382
JOHNSON & JOHNSON4.56%355 145
ROCHE HOLDING AG21.63%255 382
MERCK AND COMPANY11.11%216 154
PFIZER-14.59%206 312
NOVARTIS19.39%202 726